DLH Holdings Corp. — Q1 FY2024 Form 10-Q
Business context and reporting period. The filing covers the three months ended December 31, 2023, compared with the three months ended December 31, 2022. DLH provides technology-enabled health, research, cyber, logistics, and engineering services primarily to U.S. federal agencies. Results are unaudited; the company cautions that quarterly results are not necessarily indicative of the full fiscal year.
Key financial metrics
| Metric | Q1 FY2024 | Q1 FY2023 | Change / context |
|---|---|---|---|
| Revenue | $97.9 million | $72.7 million | Up $25.1 million, or approximately 34.5%; principally attributed to the December 2022 acquisition. |
| Operating income / margin | $6.8 million / 7.0% | $3.9 million / 5.4% | Operating margin improved. |
| Net income / diluted EPS | $2.2 million / $0.15 | $1.5 million / $0.11 | Net income increased $0.6 million. |
| Interest expense | $4.7 million | $1.8 million | Increase primarily reflects debt used to finance the acquisition. |
| Cash from operations | $5.1 million | $8.0 million | Decrease primarily attributed to lower accounts payable. |
| Cash balance | $0.1 million | $1.4 million | Cash declined $0.08 million during the quarter. |
| Debt | $174.4 million principal; $168.0 million net of deferred financing costs | — | Includes $159.0 million term loan and $15.4 million revolver balance; term loan due December 2027. |
| Liquidity | $22.8 million unused revolver capacity | — | Capacity is net of outstanding letters of credit and subject to facility conditions. Current assets were $58.6 million versus current liabilities of $58.1 million. |
| Backlog | $653.5 million; $132.3 million funded | $704.8 million; $169.9 million funded at September 30, 2023 | Both total and funded backlog declined. |
Contract costs were 80.8% of revenue, compared with 78.7% a year earlier. General and administrative costs declined to 7.9% of revenue from 10.2%. Depreciation and amortization rose to $4.3 million from $2.4 million. The company reported non-GAAP EBITDA of $11.1 million, versus $6.3 million; EBITDA is a supplemental measure, not a GAAP substitute.
Material changes versus the prior comparable period
- Revenue growth was primarily acquisition-related. HHS revenue rose to $44.3 million from $27.3 million; VA revenue was $34.7 million versus $33.7 million; and DoD revenue was $16.9 million versus $10.3 million.
- Interest expense increased substantially, while operating income and operating margin improved. The income tax provision fell to $0.01 million from $0.54 million; the reported effective tax rates were 0.4% and 26.0%, respectively.
- Operating cash flow fell to $5.1 million from $8.0 million. The prior-year quarter included the acquisition, with $180.0 million of acquisition-related investing cash outflow and $200.7 million of debt proceeds.
- DLH made voluntary term-debt prepayments of $10.8 million during the quarter. Its December 31 debt balance included a $15.4 million revolver draw.
Outlook, risks, and contingencies
- Management outlook: No specific revenue, earnings, or cash-flow guidance is provided. Management said planned operating cash flow should be sufficient to support operations for 12 months from issuance of the statements.
- VA contracts: Nine pharmacy contracts and seven logistics contracts, together generating approximately $34.7 million of quarterly revenue, were operating under bridge contracts through February 29, 2024. DLH was seeking extensions. New VA procurements were set aside for service-disabled veteran-owned small businesses; DLH expected it could continue significant work as a subcontractor if a partner received an award, but outcomes are uncertain.
- Customer and funding concentration: HHS, VA, and DoD represented 45.3%, 35.4%, and 17.2% of revenue, respectively. The company identified dependence on VA and HHS contracts as a material business risk. Continuing resolutions can delay program starts and contract awards; a CR in effect at filing funded agencies through March 1 or March 8, 2024. Management said it did not expect budget negotiations to materially affect the current business base, while noting possible CR impacts.
- Debt and rates: Borrowings bear interest at SOFR plus 4.1%; the filing reported a 9.5% rate on floating-rate debt. $105 million of debt principal was covered by floating-to-fixed swaps, which reduced quarterly interest expense by approximately $0.4 million. Management estimated a 1 percentage-point SOFR increase would raise annual interest expense by approximately $0.7 million. The company reported compliance with loan covenants.
- Other risks and contingencies: Government contract recompetes, procurement protests and set-asides, contract terminations, employee retention, inflation, and higher rates could affect results. Goodwill was $138.2 million; management reported no impairment indicator at quarter-end but warned that loss or non-renewal of a major contract could affect future valuation. The company reported no litigation believed reasonably likely to have a material adverse effect and no material changes to previously disclosed risk factors.
Most important facts for investors to verify
- Whether the VA bridge contracts were extended and the results and timing of the CMOP recompetes.
- How much of reported revenue growth and future profitability is attributable to the December 2022 acquisition, including acquisition-related amortization and financing costs.
- Whether backlog and funded backlog stabilize or continue to decline, and how much of backlog converts to funded work and revenue.
- Debt repayment, revolver usage, covenant headroom, and the effect of SOFR changes as interest-rate swaps mature.
- Cash generation and working-capital trends, particularly accounts payable, given low cash on hand and the company’s reliance on operating cash flow and revolver availability.